Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.

• Revenue in USD (TTM)0.00
• Net income in USD-460.47m
• Incorporated2020
• Employees355.00

• Location
  Cerevel Therapeutics Holdings Inc222 Jacobs Street, Suite 200CAMBRIDGE 02141United StatesUSA
• Phone+1 (212) 284-2300
• Fax+1 (302) 636-5454
• Websitehttps://www.cerevel.com/